Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 26;22(1):494.
doi: 10.1186/s13063-021-05455-7.

Understanding the benefits and burdens associated with a malaria human infection study in Kenya: experiences of study volunteers and other stakeholders

Collaborators, Affiliations

Understanding the benefits and burdens associated with a malaria human infection study in Kenya: experiences of study volunteers and other stakeholders

Primus Che Chi et al. Trials. .

Abstract

Background: Human infection studies (HIS) that involve deliberately infecting healthy volunteers with a pathogen raise important ethical issues, including the need to ensure that benefits and burdens are understood and appropriately accounted for. Building on earlier work, we embedded social science research within an ongoing malaria human infection study in coastal Kenya to understand the study benefits and burdens experienced by study stakeholders in this low-resource setting and assess the wider implications for future research planning and policy.

Methods: Data were collected using qualitative research methods, including in-depth interviews (44), focus group discussions (10) and non-participation observation. Study participants were purposively selected (key informant or maximal diversity sampling), including volunteers in the human infection study, study staff, community representatives and local administrative authorities. Data were collected during and up to 18 months following study residency, from sites in Coastal and Western Kenya. Voice recordings of interviews and discussions were transcribed, translated, and analysed using framework analysis, combining data- and theory-driven perspectives.

Findings: Physical, psychological, economic and social forms of benefits and burdens were experienced across study stages. Important benefits for volunteers included the study compensation, access to health checks, good residential living conditions, new learning opportunities, developing friendships and satisfaction at contributing towards a new malaria vaccine. Burdens primarily affected study volunteers, including experiences of discomfort and ill health; fear and anxiety around aspects of the trial process, particularly deliberate infection and the implications of prolonged residency; anxieties about early residency exit; and interpersonal conflict. These issues had important implications for volunteers' families, study staff and the research institution's reputation more widely.

Conclusion: Developing ethically and scientifically strong HIS relies on grounded accounts of volunteers, study staff and the wider community, understood in the socioeconomic, political and cultural context where studies are implemented. Recognition of the diverse, and sometimes perverse, nature of potential benefits and burdens in a given context, and who this might implicate, is critical to this process. Prior and ongoing stakeholder engagement is core to developing these insights.

Keywords: Benefits; Burdens; Challenge studies; Controlled human infection studies; Developing countries; Ethics; Human infection studies.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Geographical location of CHMI study sites in Kenya (Source: [14])
Fig. 2
Fig. 2
Kilifi malaria HIS procedures. Pre-screening, 3–4 months before screening 1st screening (Sep 2017); residency/in-patient stay, maximum 24 days after challenge; 2nd screening, 3–4 months after 1st screening (Jan/Feb 2018); review clinic, 35 days post challenge; challenge event, 5 months after 1st screening (Feb/March 2018)

References

    1. Bambery B, Selgelid M, Weijer C, Savulescu J, Pollard AJ. Ethical criteria for human challenge studies in infectious diseases. Public Health Ethics. 2015;9(1):92–103. doi: 10.1093/phe/phv026. - DOI - PMC - PubMed
    1. Franklin GM, Grady C. The ethical challenge of infection-inducing challenge experiments. Clin Infect Dis. 2001;33(7):1028–1033. doi: 10.1086/322664. - DOI - PubMed
    1. Hodgson SH, et al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol. 2014;5:686. doi: 10.3389/fmicb.2014.00686. - DOI - PMC - PubMed
    1. Shah SK, Kimmelman J, Lyerly AD, Lynch HF, McCutchan F, Miller F, et al. Ethical Considerations for Zika Virus Human Challenge Trials: Report & Recommendations. National Institute of Allergy and Infectious Diseases. February 2017. https://www.niaid.nih.gov/sites/default/files/EthicsZikaHumanChallengeSt.... Accessed 17 Nov 2020.
    1. Kapulu MC, Njuguna P, Hamaluba MM, CHMI-SIKA Study Team Controlled human malaria infection in semi-ommune Kenyan adults (CHMI-SIKA): a study protocol to investigate in vivo Plasmodium falciparum malaria parasite growth in the context of pre-existing immunity. Wellcome Open Res. 2019;3:155. doi: 10.12688/wellcomeopenres.14909.2. - DOI - PMC - PubMed